NanoViricides, Inc. (NNVC), a Healthcare Biotechnology business, saw its stock exchange 12.00 common shares, a pullback when compared to its 10-day trading volume of 17.32M.
NanoViricides, Inc. (NNVC) is confirming public disclosures in articles by various industry journals and other articles, that it is working on developing a treatment for the novel coronavirus 2019-nCoV, or the Wuhan coronavirus.
“We have already initiated a program for developing a treatment for the 2019-nCOV,” said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, “Our platform technology enables possibly the most rapid pathway for new drug development against viral diseases. Of course, we will need support from governmental and international agencies such as the US CDC, WHO, and Chinese CDC to successfully develop these treatments, and, if developed, to get them to the patients in the fastest possible time.
NanoViricides, Inc. (NNVC) stock is changing hands at $12.00, up +2.52 cents or +26.58% on the day.
NanoViricides, Inc. (NNVC) EBITDA is $-7.91M.
NanoViricides, Inc. (NNVC) Technical Research:
The average 10-day trading volume of NanoViricides, Inc. (NNVC) is 17.32M compared to 2.27M over the last 3 months which indicates a pullback in trading activity. Currently, NanoViricides, Inc. (NNVC) has a 50-day moving average of $4.27 and a 200-day moving average of $3.53. These moving averages are popular technical indicators that investors use to analyze price trends of NanoViricides, Inc. (NNVC).
Approximately 7.01% of the shares of the company are short sold from investors betting the shares will trade lower. The beta value on NanoViricides, Inc. (NNVC) stock is 1.08, indicating its 48.54% to 43.79% more volatile than the overall market.
Technically, NNVC’s short term support levels are around $10.80, $7.65 and $5.09 on the downside.
Based on technical analysis, NNVC has short term rating of Very Bullish (0.54), Intermediate rating of Bullish (0.31) and the long-term rating of Bullish (0.39) giving it an overall rating of Bullish (0.41).
NNVC is trading 843.92% off its 52 week low at $1.27 and -32.47% off its 52 week high of $17.77. Performance wise, NNVC stock has recently shown investors 119.38% an increase in a week, 361.54% an increase in a month and 417.24% an increase in the past quarter.
Furthermore, NanoViricides, Inc. (NNVC) has shown a return of 378.09% since the first of the year.
NanoViricides, Inc. (NNVC) Key Evaluation:
NanoViricides, Inc. (NNVC) is a micro-cap company with a market cap value of $86.99M. NNVC insiders hold roughly 16.51% of the shares.
On Feb-11-15 Midtown Partners Initiated NNVC as Strong Buy at $5.30.
There are currently 2.74M shares in the float and 3.70M shares outstanding. There are 7.01% shares short in NNVCs float.
The industry rank for NanoViricides, Inc. (NNVC) is 114 out of 255 ranking it at the Top 45% .
NanoViricides, Inc. (NNVC) Fundamental Data:
The growth rate on NNVC this year is 58.33 compared to an industry 10.10. However, NNVCs next year’s growth rate is 21.05 compared to an industry 14.50.
The book value per share (mrq) is 2.37 and cash per share (mrq) is 0.24. Giving them a price/book (mrq) of 5.05 compared to an industry of 3.21.
NNVC fundamental ratios shows an EPS growth vs. previous year -3.80.
About NanoViricides, Inc. (NNVC):
NanoViricides, Inc. is a development stage company focused on creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. It also focuses on the development of drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides, Inc. is headquartered in West Haven, Connecticut.